Redeye updates its estimates following Imint’s Q2 report, which was pretty much in line.
Faron has announced top-line data on dose variation from the phase I/II MATINS study with lead candi...
Solteq issued its second profit warning for 2022, with challenges in both segments and significant w...
Atria is launching a development programme to improve the competitiveness and profitability of its p...
Q2 rapporten visade positiv utveckling bland samtliga projekt och bolaget har inlett sin första fas ...
Redeye updates its view on Ngenic following the Q2 report.
Redeye updates on Zordix following another quarter with stable performance beating our estimates.
Redeye is interested to learn more about today’s news from Alzecure.
Redeye updates its estimates and fair value range to reflect the recent report.
Försenade installationer belastar omsättning i Q1 Omsättningen för Q1 uppgick till 10,4 mkr (11,7 mk...
Redeye comments on Respiratorius after its announcement of the preliminary data from the PK study wi...
Sandvik mobile crushers & screens deal in Germany Should ramp up to ~15% of German sales, says comp...
Redeye raises its estimates for Energy Save following the strong Q1 2022/23 report and continued sol...
Spherio Group AB (publ) meddelade under torsdagen den 15 september att bolaget har ingått ett avtal ...
Gasprox announced yesterday that it plans to issue a convertible note worth SEK 5.
A deep dive into Alcadon on 29 September Old financial targets to be updated 34% ’21-’24e EBITA CA...
Minskad försäljning inom Health & Wellness Den rapporterade nettoomsättningen för det andra kvartale...
NEX-22: Liraglutide for type 2 diabetes (T2D) Liraglutide (Novo’s Victoza) DKK 15bn in 2021 Precli...
Redeye sees an opportunity for investors to deepen their understanding of Efecte during its Digitali...
